Jump to main content

Australian ambassador visits CSL Behring in Marburg, Germany

CSL Behring management welcomes Australian Ambassador to Germany Philip Green.

Australian Ambassador to Germany visits CSL Behring Marburg
Photo (from left to right): Dr. Rainer Waldschmidt, Dr. Thomas Spies, Vicky Pirzas, Dr. Lars Grönke, Philip Green, Michael Schröder, Anna Fedeles, Dr. Lutz Bonacker

In Marburg, on 15 June 2021.Ambassador Philip Green and the Head of the Australian Trade Mission and Consul General Anna Fedeles met with the Managing Director of Hessen Trade & Invest GmbH Dr. Rainer Waldschmidt and Marburg's Lord Mayor Dr. Thomas Spies at the CSL Behring location in Marburg to discuss CSL Behring's significance for the pharmaceutical location, German-Australian relations, the operational business and the importance of current research and development activities.

The managing directors of CSL Behring GmbH Michael Schröder and Dr. Lutz Bonacker and the two managing directors of CSL Behring Innovation GmbH Vicky Pirzas and Dr. Lars Grönke were delighted with the high-ranking visit and the intensive German-Australian dialogue. "We are very pleased to welcome these special guests of honor to our site," said Michael Schröder. "For us as an internationally operating pharmaceutical company, this exchange with politics and business is very valuable and of great importance. Especially since we have Australian roots through our parent company, CSL Limited, headquartered in Melbourne."

Following the lively round of talks, a tour of the new M600 research and development building in Görzhausen was on the agenda. When completed in 2022, the new building will provide space for up to 600 research and development employees - an investment that underscores the Australian CSL Group's commitment to the Marburg site.

The ambassador was very impressed by his visit: "I am very happy to be here today. The industry that this site represents is very important, and I take away from today: Everyone who works here is doing something really meaningful for rare disease patients. We are proud to have an Australian company be part of such an important R&D and manufacturing environment."